The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA

Nucleic Acids Research

Volumn 43, Issue 18, 2015, Pages 8955-8963

  Vickers, Timothy A ^a   Crooke, Stanley T ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA; RIBONUCLEASE H; RNASE H1; UNCLASSIFIED DRUG; RIBONUCLEASE HI;

ARTICLE; CLEARANCE; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RNA CLEAVAGE; RNA DEGRADATION; RNA PROCESSING; RNA TRANSCRIPTION; RNA TRANSPORT; GENETIC TRANSCRIPTION; KINETICS; METABOLISM;

KINETICS; OLIGONUCLEOTIDES, ANTISENSE; RIBONUCLEASE H; RNA CLEAVAGE; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 84966345573     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkv920     Document Type: Article

References (33)

1. Bennett, C.F. and Swayze, E.E. (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol., 50, 259-293.
2. Crooke, S.T. (1999) Molecular mechanisms of action of antisense drugs. Biochim. Biophys. Acta., 1489, 30-42.
3. Crouch, R.J. and Dirksen, M.-L. (1985) Ribonucleases H. In: Linn, SM and Roberts, RJ (eds). Nucleases. Cold Spring Harbor Laboratory Press, NY, pp. 211-241.
4. Cerritelli, S.M. and Crouch, R.J. (2009) Ribonuclease H: the enzymes in eukaryotes. FEBS J., 276, 1494-1505.
5. Wu, H., Lima, W.F. and Crooke, S.T. (1999) Properties of cloned and expressed human RNase H1. J. Biol. Chem., 274, 28270-28278.
6. Wu, H., Lima, W.F., Zhang, H., Fan, A., Sun, H. and Crooke, S.T. (2004) Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J. Biol. Chem., 279, 17181-17189.
7. Lima, W.F., Vickers, T.A., Nichols, J., Li, C. and Crooke, S.T. (2014) Defining the factors that contribute to on-target specificity for antisense oligonucleotides. PLoS One, 9, e101752.
8. Vickers, T.A. and Crooke, S.T. (2014) Antisense oligonucleotides capable of promoting specific target mRNA reduction via competing RNase H1-dependent and independent mechanisms. PLoS One, 9, e108625.
9. Vickers, T.A., Freier, S.M., Bui, H.-H., Watt, A. and Crooke, S.T. (2014) Targeting of repeated sequences unique to a gene results in significant increases in antisense oligonucleotide potency. PLoS One, 9, e110615.
10. Cazenave, C., Frank, P., Toulme, J.J. and Büsen, W. (1994) Characterization and subcellular localization of ribonuclease H activities from Xenopus laevis oocytes. J. Biol. Chem, 269, 25185-25192.
11. Baker, B.F., Lot, S.S., Condon, T.P., Cheng-Flournoy, S., Lesnik, E.A., Sasmor, H.M. and Bennett, C.F. (1997) 2′-O-(2-methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J. Biol. Chem., 272, 11994-12000.
12. Seth, P.P., Siwkowski, A., Allerson, C.R., Vasquez, G., Lee, S., Prakash, T.P., Kinberger, G., Migawa, M.T., Gaus, H., Bhat, B. et al. (2008) Design, synthesis and evaluation of constrained methoxyethyl (cMOE) and constrained Ethyl (cEt) nucleoside analogs. Nucleic Acids Symp. Ser., 52, 553-554.
13. Winer, J., Kwang, C., Jung, S., Shackel, I. and Williams, P.M. (1999) Development and validation of real-time quantitative reverse transcriptase±polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal. Biochem., 270, 41-49.
14. Hashimoto, J.G., Beadles-Bohling, A.S. and Wiren, K.M. (2004) Comparison of RiboGreen and 18S rRNA quantitation for normalizing real-time RT-PCR expression analysis. Biotechniques, 36, 58-60.
15. Vickers, T.A., Zhang, H., Graham, M.J., Lemonidis, K.M., Zhao, C. and Dean, N.M. (2006) Modification of MyD88 mRNA splicing and inhibition of IL-1beta signaling in cell culture and in mice with a 2′-O-methoxyethyl-modified oligonucleotide. J. Immunol., 176, 3652-3661.
16. Ardehali, M.B. and Lis, J.T. (2009) Tracking rates of transcription and splicing in vivo. Nat. Struct. Mol. Biol., 16, 1123-1124.
17. Darzacq, X., Shav-Tal, Y., de Turris, V., Brody, Y., Shenoy, S.M., Phair, R.D. and Singer, R.H. (2007) In vivo dynamics of RNA polymerase II transcription. Nat. Struct. Mol. Biol., 14, 796-806.
18. Singh, J. and Padgett, R.A. (2009) Rates of in situ transcription and splicing in large human genes. Nat. Struct. Mol. Biol., 16, 1128-1133.
19. Maiuri, P., Knezevich, A., De Marco, A., Mazza, D., Kula, A., McNally, J.G. and Marcello, A. (2011) Fast transcription rates of RNA polymerase II in human cells. EMBO Rep., 12, 1280-1285.
20. Weil, D., Boutain, S., Audibert, A. and Dautry, F. (2000) Mature mRNAs accumulated in the nucleus are neither the molecules in transit to the cytoplasm nor constitute a stockpile for gene expression. RNA, 6, 962-975.
21. Houseley, J. and Tollervey, D. (2009) The many pathways of RNA degradation. Cell, 136, 763-776.
22. Houseley, J., LaCava, J. and Tollervey, D. (2006) RNA-quality control by the exosome. Nat. Rev. Mol. Cell Biol., 7, 529-539.
23. Siwaszek, A., Ukleja, M. and Dziembowski, A. (2014) Proteins involved in the degradation of cytoplasmic mRNA in the major eukaryotic model systems. RNA Biol., 11, 1122-1136.
24. LaCava, J., Houseley, J., Saveanu, C., Petfalski, E., Thompson, E., Jacquier, A. and Tollervey, D. (2005) RNA degradation by the exosome is promoted by a nuclear polyadenylation complex. Cell, 121, 713-724.
25. Liang, X.-H., Vickers, T.A., Guo, S. and Crooke, S.T. (2011) Efficient and specific knockdown of small non-coding RNAs in mammalian cells and in mice. Nucleic Acids Res., 39, e13.
26. Lima, W.F., Wu, H. and Crooke, S.T. (2008) The RNase H mechanism. In: Crooke, ST (ed). Antisense Drug Technology, Principles, Stratgies, and Applications. 2nd edn. CRC Press, Boca Raton, pp. 47-74.
27. Garneau, N.L., Wilusz, J. and Wilusz, C.J. (2007) The highways and byways of mRNA decay. Nat. Rev. Mol. Cell Biol., 8, 113-126.
28. Nagarajan, V.K., Jones, C.I., Newbury, S.F. and Green, P.J. (2013) XRN 5′→3′ exoribonucleases: structure, mechanisms and functions. Biochim. Biophys. Acta, 1829, 590-603.
29. Wittrup, A., Ai, A., Liu, X., Hamar, P., Trifonova, R., Charisse, K., Manoharan, M., Kirchhausen, T. and Lieberman, J. (2015) Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown. Nat. Biotech., 33, 870-876.
30. Stein, C.A., Hansen, J.B., Lai, J., Wu, S., Voskresenskiy, A., Høg, A., Worm, J., Hedtjärn, M., Souleimanian, N., Miller, P. et al. (2010) Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res., 38, e3.
31. Koller, E., Vincent, T.M., Chappell, A., De, S., Manoharan, M. and Bennett, C.F. (2011) Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res., 39, 4795-4807.
32. Hodges, D. and Crooke, S.T. (1995) Inhibition of splicing of wild-type and mutated luciferase-adenovirus pre-mRNAs by antisense oligonucleotides. Mol. Pharmacol., 48, 905-918.
33. Rhodes, D.G., Sarmiento, J.G. and Herbette, L.G. (1985) Kinetics of binding of membrane-active drugs to receptor sites. Diffusion-limited rates for a membrane bilayer approach of 1,4-dihydropyridine calcium channel antagonists to their active site. Mol. Pharmacol., 27, 612-623.